37784b02-1e45-4806-b4c3-2b3ad50dbfb3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.480
- PANCREAS_BETA_CELLS+0.480
- MYC_TARGETS_V1+0.470
- E2F_TARGETS+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.460
- MTORC1_SIGNALING+0.430
- G2M_CHECKPOINT+0.420
- GLYCOLYSIS+0.420
- MYC_TARGETS_V2+0.330
- HYPOXIA+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.380
- HEDGEHOG_SIGNALING-0.260
- MYOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.240
- BILE_ACID_METABOLISM-0.240
- INTERFERON_ALPHA_RESPONSE-0.190
- INTERFERON_GAMMA_RESPONSE-0.160
- APICAL_JUNCTION-0.120
- KRAS_SIGNALING_DN-0.120
- UV_RESPONSE_DN-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5ca9ac39-e175-4890-ba6e-9ff4709d3f37 | — | — | 0.849 |
| 2 | SRR15030865 | — | — | 0.836 |
| 3 | TCGA-UY-A78L-01A-12R-A33J-07 | — | — | 0.836 |
| 4 | MNG654 | — | — | 0.835 |
| 5 | SRR975564 | — | — | 0.833 |
| 6 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.827 |
| 7 | SRR10900569 | — | — | 0.821 |
| 8 | MNG432 | — | — | 0.814 |
| 9 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.806 |
| 10 | MNG732 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.480 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |